SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
Background: The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has not yet been established. Patients and methods: A prospective multicenter registry-based cohort study conducted from December 2020 to December 2021...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:284474 |
| Acceso en línea: | https://ddd.uab.cat/record/284474 https://dx.doi.org/urn:doi:10.1186/s13045-022-01275-7 |
| Access Level: | acceso abierto |
| Palabra clave: | SARS-CoV-2 vaccines Breakthrough SARS-CoV-2 infection Correlates of protection Hematological malignancies Allogeneic stem cell transplantation Autologous stem cell transplantation COVID-19 Vaccine Immunocompromised patients Moderna mRNA-1273 Pfzer-BioNTech BNT162b2 |
| id |
ES_8efecc69196260eb0ca3da25f891efda |
|---|---|
| oai_identifier_str |
oai:ddd.uab.cat:284474 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disordersPiñana, José Luis|||0000-0001-8533-2562López-Corral, LucíaMartino Bofarull, Rodrigo|||0000-0001-5143-4042Vazquez, Lourdes|||0000-0001-8191-0046Pérez, AriadnaMartin-Martin, Gabriel AndresGago, BeatrizSanz-Linares, Gabriela|||0000-0001-7960-7988Sánchez Salinas, Andrés|||0000-0001-9495-3555Villalon, Lucia B.Conesa-García, VenancioOlave, María TeresaCorona de Lapuerta, Magdalena|||0000-0002-6553-0171Marcos-Corrales, SaraTormo, Mar|||0000-0001-9622-1649Hernández Rivas, José Ángel|||0000-0003-4550-757XMontoro, Juan B.Rodríguez-Fernández, AliciaRisco-Gálvez, Irene|||0000-0002-3931-9938Rodríguez-Belenguer, Pablo|||0000-0001-5270-7452Hernandez-Boluda, Juan Carlos|||0000-0002-4289-3113García Cadenas, Irene|||0000-0002-2994-9055Ruíz-García, Montserrat M.Muñoz-Bellido, Juan LuisSolano, Carlos|||0000-0003-3702-0817Cedillo Cedillo, Angel|||0000-0002-0126-7044Sureda, Anna|||0000-0002-1238-6970Navarro, DavidSARS-CoV-2 vaccinesBreakthrough SARS-CoV-2 infectionCorrelates of protectionHematological malignanciesAllogeneic stem cell transplantationAutologous stem cell transplantationCOVID-19VaccineImmunocompromised patientsModerna mRNA-1273Pfzer-BioNTech BNT162b2Background: The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has not yet been established. Patients and methods: A prospective multicenter registry-based cohort study conducted from December 2020 to December 2021 by the Spanish transplant and cell therapy group was used to analyze the relationship of antibody response at 3-6 weeks after full vaccination (2 doses) with breakthrough SARS-CoV-2 infection in 1394 patients with hematological disorders. Results: At a median follow-up of 165 days after complete immunization, 37 out of 1394 (2.6%) developed breakthrough SARS-CoV-2 infection at median of 77 days (range 7-195) after full vaccination. The incidence rate was 6.39 per 100 persons-year. Most patients were asymptomatic (19/37, 51.4%), whereas only 19% developed pneumonia. The mortality rate was 8%. Lack of detectable antibodies at 3-6 weeks after full vaccination was the only variable associated with breakthrough infection in multivariate logistic regression analysis (Odds Ratio 2.35, 95% confidence interval 1.2-4.6, p = 0.012). Median antibody titers were lower in cases than in non-cases [1.83 binding antibody units (BAU)/mL (range 0-4854.93) vs 730.81 BAU/mL (range 0-56,800), respectively (p = 0.007)]. We identified 250 BAU/mL as a cutoff above which incidence and severity of the infection were significantly lower. Conclusions: Our study highlights the benefit of developing an antibody response in these highly immunosuppressed patients. Level of antibody titers at 3 to 6 weeks after 2-dose vaccination links with protection against both breakthrough infection and severe disease for non-Omicron SARS-CoV-2 variants. 22022-01-0120222022-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/284474https://dx.doi.org/urn:doi:10.1186/s13045-022-01275-7reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2844742026-06-06T12:50:31Z |
| dc.title.none.fl_str_mv |
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders |
| title |
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders |
| spellingShingle |
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders Piñana, José Luis|||0000-0001-8533-2562 SARS-CoV-2 vaccines Breakthrough SARS-CoV-2 infection Correlates of protection Hematological malignancies Allogeneic stem cell transplantation Autologous stem cell transplantation COVID-19 Vaccine Immunocompromised patients Moderna mRNA-1273 Pfzer-BioNTech BNT162b2 |
| title_short |
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders |
| title_full |
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders |
| title_fullStr |
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders |
| title_full_unstemmed |
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders |
| title_sort |
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders |
| dc.creator.none.fl_str_mv |
Piñana, José Luis|||0000-0001-8533-2562 López-Corral, Lucía Martino Bofarull, Rodrigo|||0000-0001-5143-4042 Vazquez, Lourdes|||0000-0001-8191-0046 Pérez, Ariadna Martin-Martin, Gabriel Andres Gago, Beatriz Sanz-Linares, Gabriela|||0000-0001-7960-7988 Sánchez Salinas, Andrés|||0000-0001-9495-3555 Villalon, Lucia B. Conesa-García, Venancio Olave, María Teresa Corona de Lapuerta, Magdalena|||0000-0002-6553-0171 Marcos-Corrales, Sara Tormo, Mar|||0000-0001-9622-1649 Hernández Rivas, José Ángel|||0000-0003-4550-757X Montoro, Juan B. Rodríguez-Fernández, Alicia Risco-Gálvez, Irene|||0000-0002-3931-9938 Rodríguez-Belenguer, Pablo|||0000-0001-5270-7452 Hernandez-Boluda, Juan Carlos|||0000-0002-4289-3113 García Cadenas, Irene|||0000-0002-2994-9055 Ruíz-García, Montserrat M. Muñoz-Bellido, Juan Luis Solano, Carlos|||0000-0003-3702-0817 Cedillo Cedillo, Angel|||0000-0002-0126-7044 Sureda, Anna|||0000-0002-1238-6970 Navarro, David |
| author |
Piñana, José Luis|||0000-0001-8533-2562 |
| author_facet |
Piñana, José Luis|||0000-0001-8533-2562 López-Corral, Lucía Martino Bofarull, Rodrigo|||0000-0001-5143-4042 Vazquez, Lourdes|||0000-0001-8191-0046 Pérez, Ariadna Martin-Martin, Gabriel Andres Gago, Beatriz Sanz-Linares, Gabriela|||0000-0001-7960-7988 Sánchez Salinas, Andrés|||0000-0001-9495-3555 Villalon, Lucia B. Conesa-García, Venancio Olave, María Teresa Corona de Lapuerta, Magdalena|||0000-0002-6553-0171 Marcos-Corrales, Sara Tormo, Mar|||0000-0001-9622-1649 Hernández Rivas, José Ángel|||0000-0003-4550-757X Montoro, Juan B. Rodríguez-Fernández, Alicia Risco-Gálvez, Irene|||0000-0002-3931-9938 Rodríguez-Belenguer, Pablo|||0000-0001-5270-7452 Hernandez-Boluda, Juan Carlos|||0000-0002-4289-3113 García Cadenas, Irene|||0000-0002-2994-9055 Ruíz-García, Montserrat M. Muñoz-Bellido, Juan Luis Solano, Carlos|||0000-0003-3702-0817 Cedillo Cedillo, Angel|||0000-0002-0126-7044 Sureda, Anna|||0000-0002-1238-6970 Navarro, David |
| author_role |
author |
| author2 |
López-Corral, Lucía Martino Bofarull, Rodrigo|||0000-0001-5143-4042 Vazquez, Lourdes|||0000-0001-8191-0046 Pérez, Ariadna Martin-Martin, Gabriel Andres Gago, Beatriz Sanz-Linares, Gabriela|||0000-0001-7960-7988 Sánchez Salinas, Andrés|||0000-0001-9495-3555 Villalon, Lucia B. Conesa-García, Venancio Olave, María Teresa Corona de Lapuerta, Magdalena|||0000-0002-6553-0171 Marcos-Corrales, Sara Tormo, Mar|||0000-0001-9622-1649 Hernández Rivas, José Ángel|||0000-0003-4550-757X Montoro, Juan B. Rodríguez-Fernández, Alicia Risco-Gálvez, Irene|||0000-0002-3931-9938 Rodríguez-Belenguer, Pablo|||0000-0001-5270-7452 Hernandez-Boluda, Juan Carlos|||0000-0002-4289-3113 García Cadenas, Irene|||0000-0002-2994-9055 Ruíz-García, Montserrat M. Muñoz-Bellido, Juan Luis Solano, Carlos|||0000-0003-3702-0817 Cedillo Cedillo, Angel|||0000-0002-0126-7044 Sureda, Anna|||0000-0002-1238-6970 Navarro, David |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
SARS-CoV-2 vaccines Breakthrough SARS-CoV-2 infection Correlates of protection Hematological malignancies Allogeneic stem cell transplantation Autologous stem cell transplantation COVID-19 Vaccine Immunocompromised patients Moderna mRNA-1273 Pfzer-BioNTech BNT162b2 |
| topic |
SARS-CoV-2 vaccines Breakthrough SARS-CoV-2 infection Correlates of protection Hematological malignancies Allogeneic stem cell transplantation Autologous stem cell transplantation COVID-19 Vaccine Immunocompromised patients Moderna mRNA-1273 Pfzer-BioNTech BNT162b2 |
| description |
Background: The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has not yet been established. Patients and methods: A prospective multicenter registry-based cohort study conducted from December 2020 to December 2021 by the Spanish transplant and cell therapy group was used to analyze the relationship of antibody response at 3-6 weeks after full vaccination (2 doses) with breakthrough SARS-CoV-2 infection in 1394 patients with hematological disorders. Results: At a median follow-up of 165 days after complete immunization, 37 out of 1394 (2.6%) developed breakthrough SARS-CoV-2 infection at median of 77 days (range 7-195) after full vaccination. The incidence rate was 6.39 per 100 persons-year. Most patients were asymptomatic (19/37, 51.4%), whereas only 19% developed pneumonia. The mortality rate was 8%. Lack of detectable antibodies at 3-6 weeks after full vaccination was the only variable associated with breakthrough infection in multivariate logistic regression analysis (Odds Ratio 2.35, 95% confidence interval 1.2-4.6, p = 0.012). Median antibody titers were lower in cases than in non-cases [1.83 binding antibody units (BAU)/mL (range 0-4854.93) vs 730.81 BAU/mL (range 0-56,800), respectively (p = 0.007)]. We identified 250 BAU/mL as a cutoff above which incidence and severity of the infection were significantly lower. Conclusions: Our study highlights the benefit of developing an antibody response in these highly immunosuppressed patients. Level of antibody titers at 3 to 6 weeks after 2-dose vaccination links with protection against both breakthrough infection and severe disease for non-Omicron SARS-CoV-2 variants. |
| publishDate |
2022 |
| dc.date.none.fl_str_mv |
2 2022-01-01 2022 2022-01-01 |
| dc.type.none.fl_str_mv |
Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://ddd.uab.cat/record/284474 https://dx.doi.org/urn:doi:10.1186/s13045-022-01275-7 |
| url |
https://ddd.uab.cat/record/284474 https://dx.doi.org/urn:doi:10.1186/s13045-022-01275-7 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona |
| instname_str |
Universitat Autònoma de Barcelona |
| reponame_str |
Dipòsit Digital de Documents de la UAB |
| collection |
Dipòsit Digital de Documents de la UAB |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869413174839607296 |
| score |
15,300719 |